Cigna Targets 10-14% Annual Adjusted EPS Growth Through 2030 And Launches $3 Billion Modernization Program
The health company set long-term earnings targets and reaffirmed 2026 adjusted EPS guidance of at least $30.45 at its Investor Day.
Cigna Group laid out a specific earnings growth roadmap at its Wednesday Investor Day, targeting 10-14% annual adjusted earnings per share growth through 2030 alongside a new $3 billion multi-year modernization program — and reaffirmed its full-year 2026 financial guidance in the same breath.
What The 8-K Says
The company filed an 8-K with the SEC on Wednesday disclosing the Investor Day targets. The long-term goal: average annual adjusted earnings per share growth of 10-14%, paired with roughly $50 billion in cumulative operating cash flow through the end of the decade.
For 2026, Cigna reaffirmed consolidated adjusted revenues of about $280 billion, adjusted earnings per share of at least $30.45, Evernorth Health Services adjusted income from operations of at least $6.9 billion, Cigna Healthcare adjusted income from operations of at least $4.55 billion, and a Cigna Healthcare medical care ratio — medical costs as a percentage of premiums for risk products — of 83.7% to 84.7%.
The company said it previously discussed its full-year 2026 outlook in a press release dated July 30, 2026, and on the related investor conference call.
The "Lead To One" Strategy And The $3 Billion Modernization Push
The Investor Day presentation centers on a strategy Cigna calls "Lead to One." Chief Executive Officer Brian Evanko described it as unifying the enterprise around personalization at scale.
The framework is built around three businesses: Cigna Healthcare, Evernorth Specialty & Care Services, and Evernorth Pharmacy Benefit Services. Management says the three are deliberately concentrated in complex care — the segment of health spending where costs are growing fastest.
Evernorth Specialty & Care Services alone supports more than one million patients with complex conditions and delivers more than 8 million prescriptions annually, according to the press release.
To fund the growth targets, Cigna announced a $3 billion multi-year modernization and productivity program. The initiative is aimed at streamlining internal workflows, deploying AI-enabled tools for employees, and tightening supplier and vendor management. Chief Financial Officer Ann Dennison said the program is designed to be self-funding — meaning the productivity savings are expected to cover the investment's cost.
Separately, the Cigna Group Foundation announced a $10.5 million, three-year grant program to expand community support for patients and caregivers.
What It Changes For Holders
The 10-14% annual adjusted earnings per share growth target gives investors a specific, multi-year yardstick against which to measure management's execution — something the company had not previously put in writing through 2030.
The $50 billion cumulative operating cash flow figure over that same period provides a parallel check on whether the earnings growth is translating into actual cash generation.
The 8-K notes that the outlook excludes the potential effects of any business combinations after the filing date, but does include expected future share repurchases and anticipated 2026 dividends. The company said it currently intends to pay regular quarterly dividends, with future declarations subject to board approval.
CI shares closed at $275.26 at Tuesday's close, up about 1% versus the prior session, according to market data — a move that predates Wednesday's Investor Day disclosures.
What To Watch
The clearest near-term test is whether Cigna's next quarterly results show movement toward the 10-14% adjusted earnings per share growth trajectory it has now committed to through 2030.
Investors will also be watching whether the modernization and productivity program delivers the self-funding performance Dennison promised — that is, whether the $3 billion investment generates enough savings to cover its own cost without compressing margins.
The next concrete checkpoint is Cigna's following quarterly earnings report, where the 10-14% adjusted earnings per share growth target and the medical care ratio guidance of 83.7% to 84.7% will face their first test against actual results.
